PT - JOURNAL ARTICLE AU - Richards, Alexandra S AU - Sossen, Bianca AU - Emery, Jon C AU - Horton, Katherine C AU - Heinsohn, Torben AU - Frascella, Beatrice AU - Balzarini, Federica AU - Oradini-Alacreu, Aurea AU - Hacker, Brit AU - Odone, Anna AU - McCreesh, Nicky AU - Grant, Alison D AU - Kranzer, Katharina AU - Cobelens, Frank AU - Esmail, Hanif AU - Houben, Rein MGJ TI - The natural history of TB disease-a synthesis of data to quantify progression and regression across the spectrum AID - 10.1101/2021.09.13.21263499 DP - 2022 Jan 01 TA - medRxiv PG - 2021.09.13.21263499 4099 - http://medrxiv.org/content/early/2022/06/07/2021.09.13.21263499.short 4100 - http://medrxiv.org/content/early/2022/06/07/2021.09.13.21263499.full AB - Background Prevalence surveys have found a substantial burden of subclinical (asymptomatic but infectious) TB, from which individuals can progress, regress or even persist in a chronic disease state. We aimed to quantify these pathways across the spectrum of TB disease.Methods We created a deterministic framework of TB disease with progression and regression between three states of pulmonary TB disease: minimal (non-infectious), subclinical, and clinical (symptomatic and infectious) disease. We estimated ranges for each parameter by considering all data from a systematic review in a Bayesian framework, enabling quantitative estimation of TB disease pathways.Findings Twenty-two studies contributed data from 5942 individuals. Results suggested that, after five years, 39.5%(95% uncertainty interval, UI, 31.4%-47.3%) of individuals with prevalent subclinical disease at baseline had recovered after regressing to minimal disease and 18.4%(95%UI, 13.7%-24%) had died from TB, leaving 14%(95%UI, 10.1%- 18.6%) individuals still with infectious disease at five years, and the remainder with minimal disease at risk of further progression. Over the course of five years 50.2% (95%UI, 41.1%-59%) of the subclinical cohort never developed symptoms. For those with clinical disease at baseline, 45.9%(95%UI, 38.9%-52.1%) and 19.8%(95%UI, 15.1%-25.3%) had died or recovered from TB respectively, with the remainder in, or undulating between, the three disease states. The ten-year mortality of people with untreated prevalent infectious disease was 38%.Interpretation Our results show that for people with subclinical disease, classic clinical disease is neither inevitable nor an irreversible outcome. As such, reliance on symptom- based screening means a large proportion of people with infectious disease may never be detected.Funding TB Modelling and Analysis Consortium and European Research CouncilEvidence before this study In recent years the existence of a spectrum of TB disease has been re-accepted. The classic paradigm of disease is one active state of symptomatic presentation with bacteriologically positive sputum, now referred to as clinical disease. Within the spectrum, a subclinical phase (where people do not report symptoms but have bacteriologically positive sputum) has been widely accepted, due to prevalence surveys using chest radiography screening in addition to symptom screening. On average these prevalence surveys have found around 50% of people with prevalent infectious TB had subclinical disease. There is also another state of minimal disease, or non-infectious disease, that is the earliest point on the disease spectrum after progression from infection. The likelihood or speed of natural progression, regression, or persistence of individuals across this spectrum remains unknown. As a consequence, the ability to accurately predict the impact of interventions has been limited. As individuals with bacteriologically-positive TB now receive treatment, contemporary data to inform the required transitions is highly limited. However, a large number of cohorts of patients were described in the pre-chemotherapy era. Until now, these data have not been synthesised to inform parameters to describe the natural history of TB disease.Added value of this study We synthesised data from historical and contemporary literature to explore the expected trajectories of individuals across the spectrum of TB disease. We considered a cohort of people with prevalent bacteriologically positive disease, with a 50/50 split of people with subclinical and clinical disease at baseline. We found that within five years, 29.6% of people recover from TB, defined as no chance of progressing to active disease without reinfection. However, we also find that 13.7% are still spending time infectious at the end of the five years. Our estimates for 10 year mortality and duration of symptoms before treatment aligned with the known and accepted values.We also show that regression from subclinical disease results in a large reservoir of people with minimal disease, from which they can permanently recover, but can also progress again to subclinical disease. The undulating pathways that lead to regression and progression mean that 50.2% (41.1%-59%) of individuals with prevalent subclinical disease do not experience symptoms over the course of five years. This shows that clinical disease is neither a rapid, nor inevitable outcome of subclinical disease.Implications of the available evidence With these data-driven estimates of parameters, informed projections of the relative value of addressing minimal, subclinical, or clinical disease can now be provided. Given the known reservoir of prevalent subclinical disease and its contribution to transmission, efforts to diagnose and treat people with “earlier” stages of TB are likely to have a larger impact than strategies targeting clinical disease, particularly on individuals who never would have progressed to clinical disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementASR, JCE, KCH and RMGJH received funding from the European Research Council (ERC) under the European Union's Horizon 2020 programme (Starting Grant Action Number 757699). KCH is supported by the UK FCDO (Leaving no-one behind: transforming gendered pathways to health for TB). This research has been partially funded by UK aid from the UK government (to KCH); however the views expressed do not necessarily reflect the UK government's official policies. HE, BS, received funding from the TB Modelling and Analysis Consortium (TB MAC) HE received funding from the Medical Research Council (Grant ref: MR/V00476X/1) NM is funded by the Wellcome Trust (218261/Z/19/Z) FC received no funding for this work. KK received no funding for this work. FB, BF, AOA, AO received no funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was not requiredI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the supplementary materials and references